Oriol Casanovas

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4453768/publications.pdf

Version: 2024-02-01

81 papers	7,032 citations	117625 34 h-index	82547 72 g-index
82 all docs	82 docs citations	82 times ranked	11348 citing authors

#	Article	IF	Citations
1	HighFGFR1â€“4mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer. Clinical Cancer Research, 2022, 28, 137-149.	7.0	12
2	Promalignant effects of antiangiogenics in the tumor microenvironment. Seminars in Cancer Biology, 2022, 86, 199-206.	9.6	3
3	Diffuse optical platform for the personalization of plasmonic photothermal therapy. , 2022, , .		0
4	EVI1 as a Prognostic and Predictive Biomarker of Clear Cell Renal Cell Carcinoma. Cancers, 2020, 12, 300.	3.7	9
5	Kidney cancer PDOXs reveal patientâ€specific proâ€malignant effects of antiangiogenics and its molecular traits. EMBO Molecular Medicine, 2020, 12, e11889.	6.9	4
6	Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study. Oncologist, 2019, 24, 38-46.	3.7	23
7	Antitumor Effects of Anti-Semaphorin 4D Antibody Unravel a Novel Proinvasive Mechanism of Vascular-Targeting Agents. Cancer Research, 2019, 79, 5328-5341.	0.9	21
8	RAS mutant allele fraction in plasma predicts benefit to anti-angiogenic based first-line treatment in metastatic colorectal cancer. Annals of Oncology, 2019, 30, v217.	1.2	0
9	Mechanisms of Anti-angiogenic Therapy. , 2019, , 183-208.		0
10	Uveal Melanoma, Angiogenesis and Immunotherapy, Is There Any Hope?. Cancers, 2019, 11, 834.	3.7	41
11	Quantification of gold nanoparticle accumulation in tissue by two-photon luminescence microscopy. Nanoscale, 2019, 11, 11331-11339.	5.6	17
12	Non-invasive and quantitativein vivomonitoring of gold nanoparticle concentration and tissue hemodynamics by hybrid optical spectroscopies. Nanoscale, 2019, 11, 5595-5606.	5.6	5
13	Insulinâ€like growth factor levels and chronic lymphocytic leukaemia: results from the MCC â€Spain and EpiLymphâ€Spain studies. British Journal of Haematology, 2019, 185, 608-612.	2.5	1
14	Mechanisms of Tumor Angiogenesis. , 2019, , 3-31.		2
15	ALK1 Loss Results in Vascular Hyperplasia in Mice and Humans Through PI3K Activation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 1216-1229.	2.4	75
16	A Role for CXCR4 in Peritoneal and Hematogenous Ovarian Cancer Dissemination. Molecular Cancer Therapeutics, 2018, 17, 532-543.	4.1	28
17	Endothelial cell rearrangements during vascular patterning require PI3-kinase-mediated inhibition of actomyosin contractility. Nature Communications, 2018, 9, 4826.	12.8	53
18	Unraveling the Role of Angiogenesis in Cancer Ecosystems. Frontiers in Oncology, 2018, 8, 248.	2.8	204

#	Article	IF	Citations
19	TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence. Journal of Clinical Investigation, 2018, 128, 3887-3905.	8.2	79
20	Angiogenesis and Metabolism: Entwined for Therapy Resistance. Trends in Cancer, 2017, 3, 10-18.	7.4	46
21	Sprouting strategies and dead ends in anti-angiogenic targeting of NETs. Journal of Molecular Endocrinology, 2017, 59, R77-R91.	2.5	9
22	Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition. Oncogene, 2017, 36, 2737-2749.	5.9	34
23	Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action. Targeted Oncology, 2017, 12, 19-35.	3.6	77
24	Translational research in neuroendocrine tumors: pitfalls and opportunities. Oncogene, 2017, 36, 1899-1907.	5.9	26
25	Pre-clinical longitudinal monitoring of hemodynamic response to anti-vascular chemotherapy by hybrid diffuse optics. Biomedical Optics Express, 2017, 8, 2563.	2.9	5
26	The TGFÎ² pathway stimulates ovarian cancer cell proliferation by increasing IGF1R levels. International Journal of Cancer, 2016, 139, 1894-1903.	5.1	53
27	Therapeutic Benefit of Selective Inhibition of p110Î± PI3-Kinase in Pancreatic Neuroendocrine Tumors. Clinical Cancer Research, 2016, 22, 5805-5817.	7.0	35
28	Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients. Cell Reports, 2016, 15, 1134-1143.	6.4	96
29	Antiangiogenic resistance via metabolic symbiosis. Molecular and Cellular Oncology, 2016, 3, e1211979.	0.7	3
30	Phase II study of everolimus (EVL) and octreotide (OCT) LAR in patients with non-functioning gastrointestinal neuroendocrine tumours (GI-NETs): EVERLAR study. Annals of Oncology, 2016, 27, vi145.	1.2	1
31	Scanning, non-contact, hybrid broadband diffuse optical spectroscopy and diffuse correlation spectroscopy system. Biomedical Optics Express, 2016, 7, 481.	2.9	9
32	The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients. Oncotarget, 2016, 7, 60110-60122.	1.8	16
33	MicroRNA-497 impairs the growth of chemoresistant neuroblastoma cells by targeting cell cycle, survival and vascular permeability genes. Oncotarget, 2016, 7, 9271-9287.	1.8	31
34	Antiangiogenic Resistance: Novel Angiogenesis Axes Uncovered by Antiangiogenic Therapies Research. Current Drug Targets, 2016, 17, 1728-1734.	2.1	10
35	A non-contact, small animal scanner based on diffuse optical spectroscopy and diffuse correlation spectroscopy. , 2016, , .		0
36	Simultaneous, non-invasive measurement of local tissue hemodynamics, oxygen metabolism and gold nanorod concentration in vivo. , 2016, , .		0

#	Article	IF	Citations
37	Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). Annals of Oncology, 2015, 26, 1987-1993.	1.2	112
38	A novel role for an RCAN3-derived peptide as a tumor suppressor in breast cancer. Carcinogenesis, 2015, 36, 792-799.	2.8	18
39	PTEN mediates Notch-dependent stalk cell arrest in angiogenesis. Nature Communications, 2015, 6, 7935.	12.8	86
40	Multi-target angiokinase inhibitors to fight resistance. Cell Cycle, 2014, 13, 2649-2650.	2.6	4
41	Contrasting responses of nonâ€small cell lung cancer to antiangiogenic therapies depend on histological subtype. EMBO Molecular Medicine, 2014, 6, 539-550.	6.9	21
42	The PDGFRÎ²â€“AKT Pathway Contributes to CDDP-Acquired Resistance in Testicular Germ Cell Tumors. Clinical Cancer Research, 2014, 20, 658-667.	7.0	55
43	Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets. Cancer and Metastasis Reviews, 2014, 33, 345-351.	5.9	29
44	Antiangiogenic Therapies: Going beyond Their Limits. Cancer Discovery, 2014, 4, 31-41.	9.4	90
45	Haematopoietic focal adhesion kinase deficiency alters haematopoietic homeostasis to drive tumour metastasis. Nature Communications, 2014, 5, 5054.	12.8	17
46	Relevance of Angiogenesis in Neuroendocrine Tumors. , 2014, , 29-41.		2
47	ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor. International Journal of Cancer, 2013, 133, 235-246.	5.1	16
48	Effectivity of pazopanib treatment in orthotopic models of human testicular germ cell tumors. BMC Cancer, 2013, 13, 382.	2.6	21
49	Antiâ€angiogenesis and metastasis: a tumour and stromal cell alliance. Journal of Internal Medicine, 2013, 273, 128-137.	6.0	53
50	Molecular Pathogenesis of Neuroendocrine Tumors: Implications for Current and Future Therapeutic Approaches. Clinical Cancer Research, 2013, 19, 2842-2849.	7.0	80
51	Metronomic chemotherapy following the maximum tolerated dose is an effective antiâ€tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells. International Journal of Cancer, 2013, 133, 2464-2472.	5.1	76
52	Progeny of Lgr5-expressing hair follicle stem cell contributes to papillomavirus-induced tumor development in epidermis. Oncogene, 2013, 32, 3732-3743.	5.9	46
53	Inhibition of the p110Î± isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis. Journal of Experimental Medicine, 2013, 210, 1937-1945.	8.5	56
54	Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination. Journal of Experimental Medicine, 2013, 210, 563-579.	8.5	110

#	Article	IF	Citations
55	Study on activation of the IGF-1R mTOR pathway in neuroendocrine tumours (NETs).. Journal of Clinical Oncology, 2013, 31, 4139-4139.	1.6	4
56	Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination. Journal of Cell Biology, 2013, 200, i10-i10.	5.2	0
57	Inhibition of the p110Î± isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis. Journal of Cell Biology, 2013, 202, 2027OIA99.	5.2	0
58	Exploiting pleiotropic activities of semaphorins as multiâ€target therapies for cancer. EMBO Molecular Medicine, 2012, 4, 168-170.	6.9	6
59	Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGFâ€“VEGFR2 signalling. Nature, 2012, 484, 110-114.	27.8	315
60	Limitations of therapies exposed. Nature, 2012, 484, 44-46.	27.8	42
61	Relevance of angiogenesis in neuroendocrine tumors. Targeted Oncology, 2012, 7, 93-98.	3.6	10
62	Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. Journal of Clinical Investigation, 2012, 122, 1832-1848.	8.2	154
63	Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 4394-4399.	7.1	222
64	Non-invasive monitoring of hypoxia-inducible factor activation by optical imaging during antiangiogenic treatment in a xenograft model of ovarian carcinoma. International Journal of Oncology, 2011, 39, 543-52.	3.3	3
65	The use of caspase inhibitors in pulsed-field gel electrophoresis may improve the estimation of radiation-induced DNA repair and apoptosis. Radiation Oncology, 2011, 6, 6.	2.7	5
66	Glycolytic Phenotype and AMP Kinase Modify the Pathologic Response of Tumor Xenografts to VEGF Neutralization. Cancer Research, 2011, 71, 4214-4225.	0.9	67
67	Use of a Mouse Model of Pancreatic Neuroendocrine Tumors to Find Pericyte Biomarkers of Resistance to Anti-angiogenic Therapy. Hormone and Metabolic Research, 2011, 43, 884-889.	1.5	35
68	The adaptive stroma joining the antiangiogenic resistance front. Journal of Clinical Investigation, 2011, 121, 1244-1247.	8.2	13
69	Filamin B Plays a Key Role in Vascular Endothelial Growth Factor-induced Endothelial Cell Motility through Its Interaction with Rac-1 and Vav-2. Journal of Biological Chemistry, 2010, 285, 10748-10760.	3.4	75
70	Sunitinib Inhibits Tumor Growth and Synergizes with Cisplatin in Orthotopic Models of Cisplatin-Sensitive and Cisplatin-Resistant Human Testicular Germ Cell Tumors. Clinical Cancer Research, 2009, 15, 3384-3395.	7.0	57
71	Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis. Cancer Cell, 2009, 15, 220-231.	16.8	2,168
72	Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model. Molecular Cancer Therapeutics, 2008, 7, 638-647.	4.1	61

#	Article	IF	Citations
73	New drug development in digestive neuroendocrine tumors. Annals of Oncology, 2007, 18, 1307-1313.	1.2	27
74	Incomplete inhibition of the Rb tumor suppressor pathway in the context of inactivated p53 is sufficient for pancreatic islet tumorigenesis. Oncogene, 2005, 24, 6597-6604.	5.9	30
75	Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell, 2005, 8, 299-309.	16.8	1,478
76	P38SAPK2 phosphorylates cyclin D3 at Thr-283 and targets it for proteasomal degradation. Oncogene, 2004, 23, 7537-7544.	5.9	44
77	The p21Cip1 protein, a cyclin inhibitor, regulates the levels and the intracellular localization of CDC25A in mice regenerating livers. Hepatology, 2002, 35, 1063-1071.	7.3	19
78	Osmotic Stress Regulates the Stability of Cyclin D1 in a p38SAPK2-dependent Manner. Journal of Biological Chemistry, 2000, 275, 35091-35097.	3.4	131
79	Calmodulin Binds to p21Cip1 and Is Involved in the Regulation of Its Nuclear Localization. Journal of Biological Chemistry, 1999, 274, 24445-24448.	3.4	53
80	The Protein SET Regulates the Inhibitory Effect of p21Cip1 on Cyclin E-Cyclin-dependent Kinase 2 Activity. Journal of Biological Chemistry, 1999, 274, 33161-33165.	3.4	78
81	The Cell Cycle Inhibitor p21CIPIs Phosphorylated by Cyclin A-CDK2 Complexes. Biochemical and Biophysical Research Communications, 1997, 241, 434-438.	2.1	15